Currently Viewing:
American Society of Clinical Oncology Annual Meeting
Dr Sara M. Tolaney on Challenges With Treating, Role of Clinical Trials in HER2-Positive Breast Cancer
August 08, 2018
Dr Dennis P. Scanlon on Recent Attempts to Address Clinician Burnout
August 06, 2018
Currently Reading
Dr Dennis P. Scanlon Explains Costs Associated With the Opioid Epidemic
July 27, 2018
Dr Sara M. Tolaney Discusses the Role of Adjuvant Therapy in HER2-Positive Breast Cancer
July 23, 2018
Dr Peter Paul Yu Explains Current Challenges With Precision Medicine
July 18, 2018
Where Dr Victoria Villaflor Thinks the Future of Precision Medicine Is Headed
July 08, 2018
Dr Peter Paul Yu on Progress in the Move Toward Interoperability
July 06, 2018
Dr Michael Thompson on Conducting Precision Medicine Trials in the Community Setting
July 05, 2018
Leonard Saltz: Novel Approaches to Colon Cancer, Behaviors That Impact Survival
July 02, 2018
Dr Sara M. Tolaney: Standard of Care, Novel Approaches for Treatment of HER2-Positive Breast Cancer
June 28, 2018
Dr Victoria Villaflor Discusses How Novel Therapies Have Changed Cancer Treatment
June 26, 2018
Dr Peter Paul Yu: How Next-Generation Sequencing Is Changing Cancer Care
June 21, 2018
Dr James Lin Chen on the Shift to Precision Medicine
June 18, 2018
Ellen Miller Sonet: The Importance of Cancer Care Providers Informing Patients of Treatment Costs
June 17, 2018
Dr Michael Thompson Highlights Novel Therapies Being Used in Hematologic Malignancies
June 16, 2018
Dr Leonard B. Saltz: The Role of Next-Generation Sequencing in Advancing Precision Medicine
June 14, 2018
Study Underscores Value of PROs in Improving Lung Cancer Survival
June 07, 2018
Discussing the Cost Burden of Cancer With Patients
June 06, 2018
Managing Cancer-Related Pain in the Era of the Opioid Crisis
June 06, 2018
Opdivo Plus Chemo Boosts Progression-Free Survival 26% Over Chemo Alone in Late-Stage NSCLC
June 04, 2018
Nearly Half of Patients With Metastatic CSCC Respond to Cemiplimab, on Fast Track at FDA
June 04, 2018
Cemiplimab, in GOG 3016, Looks to Break New Ground for Immunotherapy in Cervical Cancer
June 04, 2018
KEYNOTE-042 Confirms First-Line Pembrolizumab Superior to Chemotherapy in PD-L1–Low Advanced NSCLC
June 04, 2018
Phase 3 TAILORx Results Confirm Chemotherapy Unnecessary in 70% of Women With Early-Stage Breast Cancer
June 04, 2018

Dr Dennis P. Scanlon Explains Costs Associated With the Opioid Epidemic

Individuals, families, and local, state, and federal government all have incurred costs as a result of the opioid epidemic, explained Dennis P. Scanlon, PhD, professor, Health Policy and Administration, and director, Center for Health Care and Policy Research, Pennsylvania State University.


Individuals, families, and local, state, and federal government all have incurred costs as a result of the opioid epidemic, explained Dennis P. Scanlon, PhD, professor, Health Policy and Administration, and director, Center for Health Care and Policy Research, Pennsylvania State University.

Transcript

What have been the costs—not necessarily health related—that have arisen as a result of the opioid epidemic?

The opioid crisis, obviously you can’t go a day without seeing multiple news stories it seems on this issue, and it is a major issue, really a tragedy for the health of the US population. Of course, the obvious is premature death, mortality, the impact on families, and so forth and so on, but when you extend beyond that, I think you can look at the cost of the opioid crisis in a variety of different dimensions. You can look at first of all, who bears those costs, and there you can look at the individuals who are affected themselves and the family members of those individuals. You can look at state governments, local governments, as well as the federal government. So, we tend to look at cost in a variety of different buckets.

For example, if you’re a Medicaid recipient, and a Medicaid recipient has an overdose or needs treatment or therapy, often times Medicaid is incurring cost that it would not have had to occur had that overdose not happened if we were able to prevent the epidemic. Often times, individuals with addictions and with overdose get into the criminal justice system, and that involves not only sort of policing, but often times incarceration, and then judicial service cost as well. So, if you look at cost of states of having to deal with just the corrections or the judicial services associated with these cases-—whether it’s from an overdoes or addiction, or whether somebody’s supplying the drugs—there are significant expenditures there as well.

You can look at foster care costs—children who find themselves without a parent, a parent removed from the home, a parent who suffered from a premature death—and states or counties are overloaded in their foster care load as a result of this epidemic, so it really is pervasive. But, I would say criminal justice, education, special education in particular, children youth and services costs, like foster care. There certainly the medical care expenditure costs—Medicaid commercial insurers, Medicare. So it really is a pervasive epidemic, and again, individuals, families, and then local, state, and federal government all have incurred cost as a result of this epidemic.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!